Qualigen Therapeutics (QLGN) Competitors $3.58 +0.10 (+2.87%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QLGN vs. NXTC, DWTX, HOTH, TRIB, FLGC, ATHA, BLRX, SNSE, PRTG, and BTAIShould you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include NextCure (NXTC), Dogwood Therapeutics (DWTX), Hoth Therapeutics (HOTH), Trinity Biotech (TRIB), Flora Growth (FLGC), Athira Pharma (ATHA), BioLineRx (BLRX), Sensei Biotherapeutics (SNSE), Portage Biotech (PRTG), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical products" industry. Qualigen Therapeutics vs. NextCure Dogwood Therapeutics Hoth Therapeutics Trinity Biotech Flora Growth Athira Pharma BioLineRx Sensei Biotherapeutics Portage Biotech BioXcel Therapeutics NextCure (NASDAQ:NXTC) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings. Is NXTC or QLGN more profitable? Qualigen Therapeutics' return on equity of 0.00% beat NextCure's return on equity.Company Net Margins Return on Equity Return on Assets NextCureN/A -62.50% -53.67% Qualigen Therapeutics N/A N/A -424.18% Do insiders & institutionals believe in NXTC or QLGN? 42.7% of NextCure shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 13.3% of NextCure shares are owned by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate NXTC or QLGN? NextCure presently has a consensus price target of $3.50, indicating a potential upside of 652.04%. Given NextCure's stronger consensus rating and higher probable upside, analysts clearly believe NextCure is more favorable than Qualigen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Qualigen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor NXTC or QLGN? In the previous week, NextCure and NextCure both had 2 articles in the media. Qualigen Therapeutics' average media sentiment score of 1.44 beat NextCure's score of 1.43 indicating that Qualigen Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment NextCure Positive Qualigen Therapeutics Positive Which has better earnings and valuation, NXTC or QLGN? Qualigen Therapeutics has higher revenue and earnings than NextCure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNextCureN/AN/A-$62.72M-$1.98-0.24Qualigen Therapeutics$4.98M0.53-$13.42MN/AN/A Which has more volatility and risk, NXTC or QLGN? NextCure has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Does the MarketBeat Community believe in NXTC or QLGN? NextCure received 75 more outperform votes than Qualigen Therapeutics when rated by MarketBeat users. However, 87.50% of users gave Qualigen Therapeutics an outperform vote while only 65.08% of users gave NextCure an outperform vote. CompanyUnderperformOutperformNextCureOutperform Votes8265.08% Underperform Votes4434.92% Qualigen TherapeuticsOutperform Votes787.50% Underperform Votes112.50% SummaryNextCure beats Qualigen Therapeutics on 8 of the 13 factors compared between the two stocks. Get Qualigen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QLGN vs. The Competition Export to ExcelMetricQualigen TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.64M$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.4422.5718.48Price / Sales0.53242.70395.64103.60Price / CashN/A65.8538.1834.62Price / Book-0.186.516.774.25Net Income-$13.42M$143.21M$3.22B$248.23M7 Day Performance-1.65%1.97%1.46%0.89%1 Month Performance2.58%6.89%3.98%3.53%1 Year Performance-76.11%-2.52%16.14%5.09% Qualigen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QLGNQualigen TherapeuticsN/A$3.58+2.9%N/A-76.1%$2.64M$4.98M0.0050Short Interest ↓Positive NewsNXTCNextCure4.6476 of 5 stars$0.37+2.2%$3.50+848.5%-61.5%$10.35MN/A-0.1890Short Interest ↓High Trading VolumeDWTXDogwood Therapeutics2.2359 of 5 stars$5.37+25.8%N/AN/A$10.26MN/A-0.825Upcoming EarningsPositive NewsHigh Trading VolumeHOTHHoth Therapeutics3.1677 of 5 stars$0.77-2.0%$4.00+418.5%-26.3%$10.16MN/A-0.584Short Interest ↓TRIBTrinity Biotech1.6667 of 5 stars$0.56+1.5%N/A-57.0%$10.07M$59.13M-0.25480Analyst ForecastShort Interest ↓Positive NewsFLGCFlora Growth3.3284 of 5 stars$0.50-7.1%$5.00+900.0%-65.3%$9.72M$59.51M-0.38280Short Interest ↓Positive NewsATHAAthira Pharma3.2147 of 5 stars$0.25+4.1%$13.83+5,462.3%-85.7%$9.71MN/A-0.0940Gap UpBLRXBioLineRx2.2766 of 5 stars$2.90+0.7%$26.00+796.6%-87.0%$9.65M$28.94M-0.3340Gap DownSNSESensei Biotherapeutics4.6454 of 5 stars$0.38-5.8%$4.25+1,012.6%-60.1%$9.63MN/A-0.3240Upcoming EarningsNegative NewsGap DownPRTGPortage Biotech0.7595 of 5 stars$9.09+15.9%N/A+143.7%$9.54MN/A-0.226Short Interest ↓Gap DownBTAIBioXcel Therapeutics4.4409 of 5 stars$1.71-1.7%$42.60+2,391.2%-95.4%$9.38M$2.27M-0.0590Upcoming EarningsPositive News Related Companies and Tools Related Companies NXTC Competitors DWTX Competitors HOTH Competitors TRIB Competitors FLGC Competitors ATHA Competitors BLRX Competitors SNSE Competitors PRTG Competitors BTAI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QLGN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy QLGN Stock Free QLGN Stock Alerts